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A pilot retrospective analysis of 
alpha-blockers on recurrence in 
men with localised prostate cancer 
treated with radiotherapy
Jordan Hart1,2,5, Briohny Spencer1,2,5, Catherine M McDermott3,5, Russ chess-Williams3,5, 
Donna Sellers3,5, David christie2,4,5 & Shailendra Anoopkumar-Dukie1,2,5 ✉
While alpha-blockers are commonly used to reduce lower urinary tract symptoms in prostate cancer 
patients receiving radiotherapy, their impact on response to radiotherapy remains unknown. Therefore, 
this pilot study aimed to retrospectively determine if alpha-blockers use, influenced response to 
radiotherapy for localised prostate cancer. In total, 303 prostate cancer patients were included, 
consisting of 84 control (alpha-blocker naïve), 72 tamsulosin and 147 prazosin patients. The main 
outcomes measured were relapse rates (%), time to biochemical relapse (months) and PSA velocity (ng/
mL/year). Recurrence free survival was calculated using Kaplan-Meier analysis. Prazosin significantly 
reduced biochemical relapse at both two and five-years (2.72%, 8.84%) compared to control (22.61%, 
34.52%). Recurrence free survival was also significantly higher in the prazosin group. This remained 
after multivariable analysis (HR: 0.09, 95% CI: 0.04–0.26, p < 0.001). Patients receiving prazosin had 
a 3.9 times lower relative risk of biochemical relapse compared to control. Although not statistically 
significant, tamsulosin and prazosin extended recurrence free survival by 13.15 and 9.21 months 
respectively. We show for the first time that prazosin may reduce risk of prostate cancer recurrence 
and delay time to biochemical relapse and provides justification for prospective studies to examine its 
potential as an adjunct treatment option for localised prostate cancer.
Prostate cancer is the fourth most prevalent cancer worldwide and the most common solid tumour among males. 
In Australia, an estimated 17,729 new cases of prostate cancer are diagnosed each year and it is the second lead-
ing cause of cancer related death among Australian men1. Approximately 80% of new diagnoses are clinically 
localised2, with a five-year survival rate of approximately 95%1. However, the cancer will eventually transition to 
castrate resistant disease. Following this transition the disease is ultimately incurable3 with a median survival of 
14 months4.
Radiotherapy is an important treatment modality being used in approximately 60% of localised prostate can-
cer patients5. While it is an effective treatment with a five-year survival of 98.8%6, it is limited by the associated 
adverse effects. The toxicities associated with radiotherapy can be both acute and chronic in nature, and mainly 
impact the lower urinary tract causing complications which include radiation cystitis and bladder outlet obstruc-
tion, which can significantly affect a patient’s quality of life7–9. α1-adrenoceptor antagonists such as tamsulosin 
and prazosin are commonly used to relieve the voiding symptoms associated with benign prostatic hyperplasia. 
In addition, these drugs are recommended either prophylactically10 or at onset of lower urinary tract symptoms in 
men treated with radiotherapy for prostate cancer11. While α1-adrenoceptor antagonists are widely used clinically, 
their impact on the outcomes of radiotherapy have to date not been considered.
Numerous studies suggest that the α1-adrenoceptor antagonists, may possess both cytotoxic and antitumour 
effects in various in vitro models of prostate cancer, exerting cytotoxic effects via mechanisms independent to that 
of the α1-adrenoceptor blockade12–17. There is substantial evidence that the quinazoline α1 antagonists (terazosin, 
prazosin and doxazosin) display cytotoxicity in prostate cancer cell lines14,18–20, effects that are not observed with 
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the sulphonamide derivative tamsulosin21. This cytotoxicity has been observed with high concentrations of the 
α1-adrenoceptor antagonists in vitro and is thought to occur primarily via apoptotic cell death, however the com-
plete range of cell death mechanisms remains to be fully understood13,22. In vivo studies in mice have shown that 
these effects also occur at clinically relevant doses, with reduction in tumour growth, metastasis and decreased 
angiogenesis observed in models of prostate cancer23,24.
By comparison to in vitro and in vivo studies, the clinical evidence in prostate cancer patients is lacking with 
studies only evaluating the role of α1-adrenoceptor antagonists in reducing prostate cancer incidence rather than 
as a treatment option. Harris, A. et al., conducted an observational cohort study on men treated with either 
doxazosin or terazosin for benign prostatic hyperplasia or hypertension25. The study found that the incidence of 
prostate cancer in treated men compared to untreated men was lower with 7.6 fewer cases of prostate cancer per 
1000 treated men25. Similarly, Yamada et al., found that the incidence of prostate cancer was significantly lower 
for patients treated with naftopidil when compared to tamsulosin26. The only study to investigate the cytotoxicity 
of these agents in humans was performed by Keledjian et al., in benign prostatic hyperplasia patients27. These 
authors reported that terazosin increased the apoptotic index and reduced prostate vascularity in these patients27.
To our knowledge, there have been no studies to date that have investigated these agents for their potential to 
affect outcomes for radiotherapy for localized prostate cancer. Therefore, the aim of this study was to determine 
the potential of the α1-adrenoceptor antagonists as a possible adjunct treatment in patients receiving radiotherapy 
for localised prostate cancer. This was achieved retrospectively at Genesis Cancer Care Southport and investigated 
the ability of these agents to delay time to biochemical relapse and reduce prostate cancer recurrence.
Materials and Methods
Patients and ethics. Data from patients with histologically proven adenocarcinoma of the prostate who 
had received radiotherapy at Genesis Cancer Care Southport (2000 and 2017) was retrospectively analysed. 
Human research ethics was approved by Uniting Care Health Queensland for data collection at their facility 
(Reference number: 2014.20.126) and approval was also gained from the Griffith University ethics committee 
(Reference number: PHM/10/14/HREC). A waiver of informed consent was also granted by Uniting Care Health 
Queensland. Patient groups included (1) control who were α1-adrenoceptor antagonist naïve, (2) men receiving 
tamsulosin and (3) prazosin at the time of radiotherapy.
Inclusion and exclusion criteria. The Genesis Cancer Care database contained records for over 10,000 
patients, which was first refined using a number of specific keywords: tamsulosin, Flomaxtra, prazosin and 
Minipress. A search including these keywords was used to identify patients who had received an α1-adrenoceptor 
antagonist (tamsulosin and prazosin treatment groups), while a search excluding these terms identified the con-
trol group that had not received an α1-adrenoceptor antagonist. Only prostate cancer patients who had received 
radiotherapy as part of their treatment plan were included in the study. Additional criteria for inclusion were, 
age > 45 years old and no pre-existing medical conditions or other treatments that may have affected PSA. The 
exclusion criteria were: age < 45 years old, patients with any other cancer or metastatic disease, patients who had 
never received radiotherapy and patients with any pre-existing medical conditions or treatments that may have 
affected PSA. Patients with insufficient medical data were also excluded for comprehensiveness.
Data collection and end points. Following the identification of eligible patients, data was systematically 
collected using the CAS8 medical records database. The database contained notes by the radiation oncologist, 
referral letters, correspondence with other health professionals, pathology and relevant medical imaging results. 
Baseline demographic characteristics including age at diagnosis, Gleason score, tumour staging, and any treat-
ment modalities were collected. PSA values were recorded periodically from diagnosis up to 120 months (10 
years) if available. The main outcomes measured were percentage relapse, time to biochemical relapse and PSA 
velocity. Although doses were not available for each patient, typical dose ranges used at the clinic for the patients 
were 1–2 mg/day for prazosin and 0.4 mg tamsulosin/day. Treatments were started during radiotherapy and then 
continued for 2–3 months post treatment until LUTS resolved.
Risk stratification. Risk groups established by the National Comprehensive Cancer Network (NCCN) were 
used to stratify patients according to PSA at diagnosis, Gleason score and tumour staging. Low risk patients 
(85–94% five-year survival) were defined as those with a diagnostic PSA of < 10 ng/mL, Gleason score of ≤ 6 and 
tumour staging T1c or T2a. Intermediate risk patients (68–84% five year survival) were defined as those with a 
diagnostic PSA > 10 to 20 ng/mL or a Gleason score of 7 or tumour stage T2b. High risk patients (43–67% five 
year survival) were defined as those with a diagnostic PSA > 20 ng/mL or a Gleason score of 8–10 or tumour 
staging T2c/T3.
Statistical analyses. Numerical data was expressed as mean ± standard deviation and median. GraphPad 
Prism (version 7) and IBM SPSS Statistics 26 software was used for statistical testing. A two by two contingency 
table with Fisher’s exact test was used to compare the proportion of men who relapsed between groups. Analysis 
of variance (ANOVA) with Tukey-Kramer post hoc testing was used to compare time to biochemical relapse 
and PSA velocity. P values < 0.05 were considered significant. Recurrence free survival (%) was calculated and 
analysed using the Kaplan Meier method and log rank test (Mantel-Cox) on GraphPad Prism (version 7) to test 
for significance. Cox regression analysis was performed using IBM SPSS Statistics 26 software and was used to 
compare survival of patients in the tamsulosin and prazosin group to survival of those in the control group. Age, 
stage at diagnosis, Gleason score and initial PSA were used as covariates in the regression model.
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Results
Patient demographics. In total, 303 prostate cancer patients with localised disease at Genesis Cancer Care 
were identified for inclusion in the study. This consisted of 84 control patients, 72 tamsulosin treated patients and 
147 prazosin treated patients. Based on the exclusion criteria described in the methods section, 219 other patients 
were excluded from the study.
The mean age at diagnosis for the whole cohort was 68.38 ± 6.71 years. In the control group the mean age 
was 68.54 ± 7.27 years while in the tamsulosin and prazosin groups the mean age was 66.81 ± 5.52 and 69.06 ± 
5.68 years respectively (Table 1). A statistical comparison of age between groups yielded only a minor significant 
difference between the tamsulosin and prazosin groups (*p = 0.0210).
The mean PSA at diagnosis in the control, tamsulosin and prazosin groups was 16.76 ± 15.89, 13.63 ± 10.26 
and 14.97 ± 17.52 ng/mL respectively with no significant difference in PSA at diagnosis identified between 
groups.
Following stratification into risk groups using the NCCN guidelines described in the methods section, it was 
observed that a higher proportion of patients in both tamsulosin (62.50%) and prazosin groups (57.10%) were 
identified as high risk when compared to control (41.70%). Similarly, both treatment groups were shown to have 
a higher proportion of patients with locally advanced disease (defined by the European Association of Urology 
(EAU) as tumour staging at diagnosis of T3 or T4)28. In the tamsulosin group 38.90% of patients were diagnosed 
with T3/T4 disease while 19.10% of prazosin patients received the same diagnosis. In comparison, only 14.30% 
of control patients had T3 disease with no patients identified as having T4 disease at diagnosis. Further to this, 
prostate biopsy pathology results revealed that 41.50% of tamsulosin patients and 43.50% of prazosin patients 
had a Gleason score of 8–10 indicative of high grade, poorly differentiated prostate cancer29. In contrast, only 
25% of control patients had a Gleason score of 8–10 at initial diagnosis. The full patient demographics are shown 
in Table 1.
Relapse rates. During the observational period, 78 patients (25.74%) were diagnosed with relapsed pros-
tate cancer. This included 35 control, 28 tamsulosin and 15 prazosin patients. Percentage relapse for the control 
group was found to be significantly higher at both the two and five-year time points when compared with pra-
zosin (*p < 0.001) (Table 2). Similarly, percentage relapse for tamsulosin was significantly higher than prazosin 
(*p = 0.011, *p = 0.0019). No significant difference was identified between the control and tamsulosin groups 
(p = 0.3905, p = 0.2231).
The control group had a 34.52% cumulative incidence at the five-year point while the cumulative incidence 
for prazosin was 8.84%. This resulted in a calculated risk ratio of 0.256 (95%CI: 0.141, 0.465) and risk difference 
of −0.257. A comparison was also made between the two α1-adrenoceptor antagonist treatment groups which 
resulted in a risk ratio of 0.354 (95%CI: 0.1837, 0.6813) and risk difference of −0.162.
Recurrence free survival is an important measure of treatment effectiveness and has been used to evaluate a 
number of treatments for localised prostate cancer30–32. In this study, Kaplan Meier curves (Fig. 1) were used to 
Characteristic at 
diagnosis
Control 
(n = 84)
Tamsulosin 
(n = 72)
Prazosin 
(n = 147)
Age (years)
Mean ± SD 68.54 ± 7.27 66.81 ± 5.52 69.06 ± 5.68*p = 0.021
Median 69 70 67
PSA (ng/mL)
Mean 16.76 ± 15.89
13.63 ± 
10.26 14.97 ± 17.52
Median 12 9.40 11
Risk Stratification Column1 Column2 Column3
Low 8 (9.50%) 6 (8.30%) 6 (4.10%)
Intermediate 41 (48.80%) 21 (29.20%) 57 (38.80%)
High 35 (41.70%) 45 (62.50%) 84 (57.10%
Tumour staging
T1 13 (15.50%) 18 (25.00%) 35 (23.80%)
T2 43 (51.20%) 25 (34.70%) 70 (47.60%)
T3 12 (14.30% 28 (38.90%) 25 (17.00%)
T4 0 (0.00%) 0 (0.00%) 3 (2.10%)
Unknown 16 (19.00%) 1 (1.40%) 14 (9.50%)
Gleason sum
3–6 29 (34.50%) 7 (9.70%) 15 (10.20%)
7 32 (38.10%) 34 (47.20% 64 (43.50%)
8–10 21 (25.00%) 30 (41.70%) 64 (43.50%)
Unknown 2 (2.40%) 1 (1.40%) 4 (2.80%)
Table 1. Demographics of prostate cancer patients at diagnosis. (*Prazosin vs tamsulosin).
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compare recurrence free survival (%) between the control and treatment groups. Analysis indicated that recur-
rence free survival (%) was significantly higher and median survival was extended in the prazosin group when 
compared to the control and tamsulosin groups (median recurrence free survival undefined in the prazosin group 
vs 72 months in both control and tamsulosin groups). Median survival is reported as undefined for the prazosin 
group as survival exceeds 50% at the ten-year mark. Log-rank (Mantel-Cox) testing indicated a significant differ-
ence between survival curves (*p < 0.0001). The results for unadjusted COX regression analyses for tamsulosin 
and prazosin groups compared to control indicate that tamsulosin had no significant effect on survival (HR: 0.63, 
95% CI: 0.35–1.14, p = 0.124) when compared to control, however use of prazosin was associated with a signif-
icant increase in survival (HR: 0.17, 95% CI: 0.08–0.35, p < 0.001). When adjusted for covariates; age, staging, 
Gleason score and initial PSA, the same trend was evident, with a stronger significant association between greater 
survival in prazosin patients with a HR of 0.09 (95% CI: 0.04–0.26, p < 0.001). The adjusted hazard ratio for the 
tamsulosin group was 0.46 (95% CI: 0.20–1.06, p = 0.067).
Time to biochemical relapse. For this study, biochemical relapse was defined by the phoenix definition 
of a PSA rise of >2 ng/ml above the nadir which was identified as the most robust determinant of patient out-
comes33. This definition allowed for the calculation of time to biochemical relapse in each group as shown in 
Table 3. The mean time to biochemical relapse in the control group was 35.71 ± 27.36 months compared to 
48.86 ± 31.73 and 45 ± 19.00 months in the tamsulosin and prazosin groups. Univariate analyses showed time 
to biochemical relapse did not differ significantly between groups (p = 0.1258). Despite the lack of statistical sig-
nificance, tamsulosin and prazosin were found to extend time to biochemical relapse by 13.15 and 9.29 months 
respectively when compared to the control group. Interestingly, median time to biochemical relapse in both tam-
sulosin and prazosin groups were equal (48 months) however mean time was increased in the tamsulosin group.
PSA velocity. PSA velocity is used as a prognostic factor to determine risk of relapse after treatment34. This 
was calculated using linear regression analysis31,35,36 and all available PSA values from three months’ post radio-
therapy up until the last available pathology result were included (Table 4). For relapsed patients, only PSA values 
prior to biochemical relapse were included in this calculation. As shown in Table 4, prazosin patients had a lower 
PSA velocity (0.31 ng/mL/year) when compared to the control (2.98 ng/mL/year) and tamsulosin (3.36 ng/mL/
year) groups.
Relapse rates (%) Control Tamsulosin Prazosin
% patients relapse 
- 2 years
22.61% 
(n = 19)***P < 0.001
15.27% 
(n = 11) 
*p = 0.011
2.72% 
(n = 4)
% patients relapse 
- 5 years
34.52% (n = 29) 
***p < 0.001
25.00% 
(n = 18) 
*p = 0.0019
8.84% 
(n = 13)
Table 2. Two and five-year percentage (%) relapse rates in control, tamsulosin and prazosin treatment groups. 
(*vs Prazosin).
Figure 1. Kaplan Meier plot of recurrence free survival (%) in control, tamsulosin and prazosin treatment 
groups for a period of 120 months (10 years).
Time to biochemical 
relapse (months)
Control 
(n = 35)
Tamsulosin 
(n = 28)
Prazosin 
(n = 15)
Mean ± SD 35.71 ± 27.36 48.86 ± 31.73 45 ± 19.00
Median 24.00 48.00 48.00
Range 105.00 114.00 68.00
Table 3. Time to biochemical relapse (months) in control, tamsulosin and prazosin treatment groups. Data is 
reported as mean ± standard deviation, median and range.
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Discussion
Prostate cancer is extremely treatable with a five-year survival rate of 95%, however it is estimated that between 
20–50% of patients will experience biochemical relapse within 10 years depending on treatment choice37. 
Currently, only a limited number of relatively invasive treatment options exist such as radiotherapy, radical 
prostatectomy, androgen deprivation and chemotherapy however these are associated with a number of adverse 
effects, toxicities as well as the development of treatment resistance. Therefore, there is an urgent need to iden-
tify effective primary or adjunct treatment options and the α1-adrenoceptor antagonists may represent one 
of these options. Numerous experimental studies have demonstrated the cytotoxic activity of the quinazoline 
based α1- adrenoceptor antagonists in both androgen dependent and castrate resistant cell lines12–20,38,39. This 
cytotoxic effect was not demonstrated with the sulphonamide derivative tamsulosin. The cytotoxic effects of the 
quinazoline α1- adrenoceptor antagonists appears to be mediated by apoptotic and antiangiogenic effects and is 
believed to occur via a mechanism largely independent to that of the α1-adrenoceptor blockade39. In addition, in 
vivo studies have shown these agents are able to significantly reduce tumour weight and suppress metastasis in 
mice40. Although sufficient in vitro/in vivo evidence exists, the limited human evidence has primarily evaluated 
the potential of the α1-adrenoceptor antagonists in reducing the risk of prostate cancer. To our knowledge, there 
are no studies to date which have investigated the role of the quinazoline α1-adrenoceptor antagonists as a novel 
adjunct treatment option for prostate cancer and as such this is the first study to retrospectively investigate the 
ability of these agents in delaying time to biochemical relapse and reducing recurrence in prostate cancer patients. 
In our study, 303 patients were identified for inclusion. All patients had histologically proven adenocarcinoma of 
the prostate and all patients had received some form of radiotherapy as part of their treatment regimen.
Three primary outcomes were used to assess the effectiveness of prazosin and tamsulosin in delaying or pre-
venting prostate cancer biochemical relapse. These outcomes included relapse rate (%), time to biochemical relapse 
(months) and PSA velocity (ng/mL/year). Relapse rates and time to biochemical relapse are outcomes which are 
frequently used in investigating the effectiveness of prostate cancer treatments41,42. Here we show that prazosin, at 
clinically used doses, significantly reduced the number of patients who experienced biochemical relapse at both 
the two and five-year points when compared to the control and tamsulosin groups. Kaplan Meier survival analysis 
demonstrated that recurrence free survival (%) was strikingly higher in the prazosin group and median survival 
was significantly extended. These results provide strong evidence that the quinazoline α1-adrenoceptor antagonist 
prazosin can improve treatment outcomes by dramatically reducing the number of patients who experience bio-
chemical relapse following radiotherapy. In contrast, the sulphonamide derivative tamsulosin was found to have 
no significant effect on both two and five-year relapse rates or recurrence free survival.
Evaluation of risk ratio using the five-year percentage relapse rates indicated that prazosin patients have a 
3.9 times lower relative risk of biochemical relapse when compared to control. Interpretation of the risk differ-
ence indicated that 257 fewer prostate cancer cases would have developed per 1000 treated men, in this case 38 
additional cases of cancer recurrence could have been expected had the patients not received prazosin. This is 
consistent with previously reported observations which found benign prostatic hyperplasia patients treated with a 
quinazoline α1- adrenoceptor antagonist resulted in a significantly reduced number of prostate cancer cases when 
compared to control patients (7.6 per 1000)25, however provides conflicting evidence to the study performed by 
Murtola et al., which indicated that α1-adrenoceptor antagonist use resulted in increased risk of biochemical 
relapse in prostate cancer43.
Time to biochemical relapse was defined by the phoenix definition of a PSA rise of > 2 ng/ml above the nadir 
and this outcome was compared between the control and two treatment groups44. Interestingly, although the two 
and five-year percentage relapse were significantly lower in the prazosin group when compared with the control 
and tamsulosin groups there was no significant difference in the time to biochemical relapse. Despite the lack of 
significance, time to relapse in both the tamsulosin and prazosin groups was extended by 13.15 and 9.21 months 
respectively. In the setting of cancer treatment with the objective of prolonging life, this is a clinically significant 
finding.
While methods such as PSA monitoring and PSA doubling time have traditionally been used as a prognostic 
tool for prostate cancer, PSA velocity is now being increasingly used due to its potential for increased specificity 
in prostate cancer detection45,46. Our results indicated that prazosin patients had a much lower PSA velocity 
when compared to the control and tamsulosin groups. While no statistical significance was identified between 
the control and prazosin group, this result is of clinical significance as previous studies have shown that a PSA 
velocity above 0.35–2 ng/mL/year can increase the risk of prostate cancer between 5.3 and 10 fold46,47. The pra-
zosin group was the only cohort to remain below this threshold in this study indicating that this agent plays a key 
role in reducing the risk of recurrence in prostate cancer patients. Consistent with in vitro evidence, tamsulosin 
demonstrated no significant effect on lowering PSA velocity and therefore reducing the risk of prostate cancer.
Consistent with in vitro and animal studies demonstrating the cytotoxic actions of the quinazoline 
α1-adrenoceptor antagonist prazosin, we show here for the first time that prazosin, at clinically relevant doses is 
able to significantly reduce the risk of prostate cancer recurrence as well as delay time to biochemical relapse in 
PSA velocity 
(ng/mL/year) Control Tamsulosin Prazosin
Mean ± SD 2.98 ± 10.99 3.36 ± 15.80 0.31 ± 2.15
Median 0.075 0.086 0.010
Table 4. Comparison of PSA velocity (ng/mL/year) for all patients in the control, tamsulosin and prazosin 
groups. Data is reported as mean ± standard deviation and median.
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prostate cancer patients following radiotherapy. Although the sulphonamide derivative tamsulosin delayed time 
to biochemical relapse, there was no significant effect on two and five-year relapse rates or PSA velocity. This is 
consistent with in vitro evidence which demonstrated no cytotoxic actions of tamsulosin even at suprapharmaco-
logical concentrations21. Therefore, while some of the actions of prazosin may involve α1 adrenoceptor blockade 
it is likely that the majority of the effects observed in this study are independent to the α1-adrenoceptor as seen 
in in vitro and animal studies13. While the effects may involve several of the in vitro targets shown to mediate 
cytotoxicity such as VEGF, EGFR, HER2/Neu, caspase 8/3, topoisomerase 1 and other mitochondrial apoptotic 
inducing factors, further studies investigating the mechanisms are needed13,23,48,49. However, despite a lack of 
clear mechanism/s, the results from this study provide a strong argument for the clinical use of the quinazoline 
α1- adrenoceptor antagonists in the treatment of prostate cancer. Despite this, further investigation from a pro-
spective clinical trial using these agents must be performed to establish their role as either an adjunct or primary 
treatment option.
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